Dosage forms for use in the treatment or prevention of disease

Abstract

The present invention relates to a dosage form comprising a biologically active ingredient for use in the treatment or prevention of a disease in the animal or human body, which treatment or prevention requires a release of 50% or more of the biologically active ingredient in the small intestine within a pH range of 3 to 5.5, the dosage form comprising: a) a core comprising the biologically active ingredient; b) an intermediate coating layer (IML) on or overlying the core, the intermediate coating layer comprising an alkaline agent; and c) an enteric coating layer (ECL) on or overlying the intermediate coating layer, the intermediate coating layer comprising an enteric polymer, wherein the relationship between the alkaline agent and the enteric polymer in the dosage form is represented by the following formula: 5-95% calculated using TIFF2023505882000026.tif15151 and biologically active ingredients that are proton pump inhibitors belonging to the class of substituted benzimidazole compounds are excluded.

Description

[Technical field]

[0001] The present invention is in the field of dosage forms, in particular pharmaceutical and dietary supplement fields, containing biologically active ingredients for use in the treatment or prevention of disease in the animal or human body.

[0002] Background technology US Patent No. 4,786,505 describes an oral pharmaceutical formulation comprising (a) a core region containing an effective amount of a material selected from the group consisting of omeprazole and an alkaline-reactive compound, an alkaline omeprazole salt and an alkaline compound, and an alkaline omeprazole salt only, (b) an inert subcoating disposed on said core that is soluble in water or rapidly disintegrates, said inert subcoating comprising one or more layers of a material selected from tablet excipients and polymeric film-forming compounds, and (c) an outer layer disposed on said subcoating comprising an enteric coating. The subcoating layer also functions as a pH buffer zone. The pH buffering properties of the subcoating layer can be further enhanced by incorporating a substance selected from the group of compounds commonly used in antacid formulations, such as oxides, hydroxides or carbonates of magnesium, hydroxides, carbonates or silicates of aluminum or calcium, complex aluminum / magnesium compounds, such as [Al2O3.6MgO.CO2.12H2O or MgO.AlO3.2SiO2.n-H2O], where n is not an integer and is less than 2. The objective of U.S. Pat. No. 4,786,505 is to provide an enteric coated dosage form of omeprazole that is resistant to dissolution in acidic media and dissolves rapidly in neutral to alkaline media and has good stability during long-term storage. In Examples 1 and 6 of U.S. Pat. No. 4,786,505, the percentage of alkaline material (magnesium oxide or aluminum hydroxide / magnesium carbonate) in the subcoating layer, calculated relative to the weight of the alkaline agent and enteric polymer (hydroxypropyl methylcellulose phthalate) in the enteric coating layer, is about 4.1 or 6.6% by weight, respectively.

[0003] US 2005 / 0214371 describes a stable composition of an acid-labile drug comprising a) an inner core having an acid-labile drug, b) a first intermediate coating free of an alkaline stabilizer and an acid-labile drug, c) a second intermediate coating containing an alkaline stabilizer, and d) an outer enteric lining in which the acid-labile drug is capable of degrading at pH 3. The term "acid-labile drug" refers to any drug or drug product or active pharmaceutical ingredient (API) that degrades at pH 3. Examples of "acid-labile drugs" include pharmaceutically active substituted benzimidazole compounds, statins (e.g., pravastatin, fluvastatin, and atorvastatin), antibiotics (e.g., penicillin G, ampicillin, streptomycin, clarithromycin, and azithromycin), dideoxycytosine (ddC), digoxin, pancreatin, bupropion, and pharmaceutically acceptable salts thereof, such as buprion HCl. The term "pharmaceutical active substituted benzimidazole compound" refers to any pharmaceutical active substituted 2-(2-pyridylmethyl)-sulfinyl-1H-benzimidazole compound (e.g., lansoprazole, omeprazole, hydroxyomeprazole, pantoprazole, rabeprazole, esomeprazole, preprazole, pariprazole, rabeprazole and tenatoprazole) and pharmaceutical active substituted 2-(phenylmethyl)-sulfinyl-1H-benzimidazole compound (e.g., leminoprazole).US Patent Application No. 2005 / 0214371 does not mention or suggest the unexpected release of acid-labile drugs at low pH values.

[0004] US Patent Application Publication No. 2005 / 0214371 provides a method for treating a disease selected from gastric or duodenal ulcer, severe erosive esophagitis, Zollinger-Elison syndrome, gastroesophageal reflux, and Helicobacter pylori infection comprising administering to a subject afflicted with the disease, preferably a subject in need of treatment, an effective amount of the stable pharmaceutical composition of the invention, wherein the acid-labile drug in the stable pharmaceutical composition is selected from lansoprazole, omeprazole, pantoprazole, rabeprazole, hydroxyomeprazole, esomeprazole, pariprazole, preprazole, tenatoprazole, leminoprazole, and acceptable salts thereof.

[0005] IPCOM000009757D (IP.com Prior Art Database Technical Disclosure IP.com Number IPCOM000009757D, IP.com electronic publication date September 17, 2002, Authors et al: Disclosed Anonymously) describes "Stabilized Pharmaceutical Formulation of an Acid-labile Benzimidazole Compound and its Preparation". The general disclosure IPCOM000009757D is very similar to the disclosure of US Patent Application No. 2005 / 0214371, except that "b) an initial intermediate coating lacking an alkaline stabilizer and an acid-labile drug" is not mentioned. IPCOM000009757D does not mention the unexpected premature release of the active pharmaceutical ingredient contained therein.

[0006] US Pat. No. 7,932,258 describes the use of partially neutralized (meth)acrylate copolymers as coatings to produce pharmaceutical dosage forms that release active substances at reduced pH values.

[0007] WO 2008 / 135090 discloses a method for preparing partially neutralized anionic (meth)acrylate copolymers or water-soluble neutral polymers of C2-C 16 It describes a dosage form that includes two individual coatings, which may include an inner coating that includes a carboxylic acid in combination with an anionic (meth)acrylate copolymer that is less neutralized than the material of the inner coating or not neutralized at all. The intended effect is that in vivo the solid dosage form releases its active substance "faster", i.e. already at the intestinal entrance. The term "faster" here means that the solid dosage form according to the invention starts to release the active substance at a pH value that is already low compared to the normal pH of the intestine, i.e. when the solid dosage form is transferred from the stomach, which has a low pH, to the intestinal entrance, which has a higher pH compared to the stomach but not as high as in the more distal parts of the intestine (e.g. pH 5.6). Compared to the standard EUDRAGIT® L100-55 coating, which shows almost no release of the active substance at pH 5.6, the double coating system releases about 30% of the active substance at the same pH in 45 minutes.

[0008] Summary of the Invention US Patent No. 4,786,505, US Patent Application No. 2005 / 0214371 and IPCOM000009757D provide stable pharmaceutical compositions for acid-labile substances, such as substituted benzimidazole compounds, especially omeprazole or pantoprazole substance families. To provide pH stability during storage conditions, a buffer alkaline substance is included in the intermediate coating layer. The outer enteric coating layer must protect the substance from contact with gastric acid. US Patent No. 4,786,505, US Patent Application No. 2005 / 0214371 and IPCOM000009757D do not provide data on the release of biologically active ingredients at pH values ​​present after gastric passage. This may be inferred by the teachings directed to the acid-labile properties of the selected substances, and already attempting release at pH values ​​between 3 and 5.5 does not make much sense.

[0009] WO 2008 / 135090 discloses a method for preparing partially neutralized anionic (meth)acrylate copolymers or water-soluble neutral polymers of C2-C 16 It describes a dosage form that includes two individual coatings, which may include an inner coating that includes a carboxylic acid in combination with an outer coating that includes an anionic (meth)acrylate copolymer that is less neutralized than the material of the inner coating or not neutralized at all. The intended effect is that the solid dosage form releases its active substance "faster" in vivo, i.e., as early as at the entrance to the intestine. The effect appears to be limited to pH values ​​below about pH 5.6.

[0010] US Patent No. 7,932,258 describes the use of partially neutralized (meth)acrylate copolymers as coatings to produce pharmaceutical dosage forms that release active substances at reduced pH values. However, in practice, the reported effect of the single coating system appears to be mitigated when the composition is first tested in an acidic medium pH 1.2 for 2 hours and then in a medium with a lower pH of 3 to 5.5.

[0011] There is a need for a dosage form for use in the treatment or prevention of a disease in the animal or human body, which treatment or prevention requires a release of 50% or more of a biologically active ingredient in the small intestine within a pH range of 3 to 5.5. The object of the present invention is solved as claimed.

[0012] Detailed Description Dosage form The present invention relates to a dosage form comprising a biologically active ingredient for use in the treatment or prevention of a disease in the animal or human body, the treatment or prevention providing a 50% or greater release of the biologically active ingredient in the small intestine within a pH range of 3 to 5.5, the dosage form comprising: a) a core comprising a biologically active ingredient; b) an intermediate coating layer (ICL) on or over the core, the intermediate coating layer comprising an alkaline agent; and c) an enteric coating layer (ECL) on or over the intermediate coating layer, which comprises an enteric polymer; wherein the relationship between the alkaline agent and the enteric polymer in the dosage form is as follows:

number

[0013] The dosage form may usually have the form of a core, which as disclosed is further coated with an intermediate coating layer and an enteric coating layer, e.g., in the form of (coated) pellets (cores). Furthermore, some single dosage forms may be included in multiples as part of a multiple unit dosage form, e.g., a capsule or tablet may include multiple dosage forms of the invention, e.g., in the form of (coated) pellets (cores).

[0014] The dosage form may, for example, have the form of tablets, minitablets, pellets, pills, granules, sachets or capsules. The dosage form may preferably be comprised in multiple units, for example tablets, sachets or capsules.

[0015] Release of biologically active ingredients Preferably, the release of the biologically active ingredient is less than 10% at pH 1.2 for 120 minutes and more than 50% (50-100%) at pH 3.2, preferably 60-100% for 45 minutes at pH 3-5.5. The pH 1.2 test medium may be 0.1N HCl according to USP, e.g. USP42, and the pH 3-5.5 medium may be a buffer medium according to USP, e.g. USP42(2019).

[0016] core The core of the dosage form comprises the biologically active ingredient.

[0017] The core of the dosage form may contain a biologically active ingredient that is distributed in a matrix structure, or bound to a binder in a coating on an inner core structure, or encapsulated.

[0018] The cores may be prepared by methods such as granulation, extrusion, spheronization or hot melt extrusion.

[0019] The core may be a pellet, pill, granule, tablet or capsule.The core may be a pellet, pill, granule, tablet or capsule.The core may be a tablet containing the active ingredient, a compressed tablet containing pellets, a mini-tablet or capsule, which may be filled with pellets or granules containing the active ingredient, with a solution or dispersion of the drug, with mini-tablets or powders, or a combination thereof.

[0020] The core may, for example, comprise uncoated pellets, neutral carrier pellets, such as sugar spheres or non-pareilles, on which the biologically active ingredient is bound to a binder, such as lactose, polyvinylpyrrolidone or neutral cellulose derivatives, such as HPC or HPMC. The binder coating layer with the biologically active ingredient is considered herein as part of the core. The binder coating layer of the core, in contrast to the intermediate coating layer and the enteric coating layer, has essentially no effect on the controlled release of the biologically active ingredient. The core may comprise uncoated pellets of crystallized biologically active ingredient.

[0021] The core may comprise 1-100%, 2-90%, 5-85%, 10-70%, 15-50% by weight of a biologically active ingredient. The core may comprise 0-99%, 10-98%, 15-95%, 30-90% or 50-85% by weight of a pharma- ceutical or nutraceutical acceptable excipient. The biologically active ingredient and the pharma-ceutical or nutraceutical acceptable excipient may total 100%.

[0022] The biologically active ingredient may be included in the core of the dosage form in an amount of 0.1 to 100% by weight of the core.

[0023] Biologically Active Ingredients Biologically active ingredients may include biologically active pharmaceutical ingredients and biologically active dietary supplement ingredients.

[0024] The biologically active ingredient that is a proton pump inhibitor belonging to the class of substituted benzimidazole compounds is excluded from the scope of the present invention.The term proton pump inhibitor is well known to those skilled in the art of pharmaceutical science.The main pharmaceutical action of proton pump inhibitor is a significant and long-lasting reduction in gastric acid production.Therefore, the term proton pump inhibitor belonging to the class of pharmaceutical activity refers to a substituted benzimidazole compound that has pharmaceutical proton pump inhibitor activity. In particular, the term proton pump inhibitors belonging to the class of pharmaceutically active substituted benzimidazole compounds refers to pharmaceutically active substituted 2-(2-pyridylmethyl)-sulfinyl-1H-benzimidazole compounds (e.g., lansoprazole, omeprazole, hydroxyomeprazole, pantoprazole, rabeprazole, esomeprazole, preprazole, pariprazole, rabeprazole and tenatoprazole) and pharmaceutically active substituted 2-(phenylmethyl)-sulfinyl-1H-benzimidazole compounds (e.g., leminoprazole).

[0025] disease The biologically active categories related to the treatment or prevention of diseases and diseases are gastrointestinal cleansing and laxatives, inflammatory bowel disease and corticosteroids, hypercholesterolemia or hypertriglyceridemia and statins, CHF and glycosides, cardiac arrhythmia and stereoisomers of quinidine, cancer and plant alkaloids, bacterial infections and antibiotics, HIV and nucleosides, pancreatic insufficiency and lipase, major depressive disorder (MDD) or seasonal affective disorder (SAD) or smoking cessation and norepinephrine / dopamine reuptake inhibitors (NDRIs), pain and inflammation and NSAIDs, rheumatoid arthritis, osteoarthritis or ankylosing spondylitis and NSAIDs, Parkinson's disease and NSAIDs, and inflammatory bowel disease and NSAIDs. The therapeutic agent may be selected from: Chronic Lymphoma and dopamine precursors, malaria and antimalarials, hypertension and beta-blockers, diabetes and biguanides, oedema or chronic renal failure and benzoic acid sulfonamide furans, mild to severe heart failure, left ventricular dysfunction after myocardial infarction, hypertension with ventricular ejection fraction ≦40%, beta-adrenergic receptor blockers, systemic fungal infections and antifungals, hyperlipoproteinemia or hypertriglyceridemia and fibrate antilipidaemia, heart failure and mineralocorticoid hormones, cancer and anthracycline antibiotics, prophylaxis of hypertension, angina or cluster headache and calcium channel blockers, atrial fibrillation and beta-blockers.

[0026] Diseases and biologically active ingredients related to the treatment or prevention of diseases include gastrointestinal cleansing and bisacodyl, inflammatory bowel disease and budesonide, hypercholesterolemia or hypertriglyceridemia and fluvastatin, CHF and digoxin, cardiac arrhythmia and quinidine, cancer and etoposide, ulcers and gastroesophageal reflux disease (GERD), omeprazole, lansoprazole, pantoprazole or rabeprazole, bacterial infections and erythromycin, penicillin G, ampicillin, streptomycin, clarithromycin or azithromycin, HIV and dideoxyinosine (ddI or didanosine), dideoxyadenosine (ddA) or dideoxycytosine (ddC), pancreatic insufficiency and lipase, major depressive disorder (MDD) or seasonal affective disorder (SAD), or smoking cessation and bleomycin. propionate, aiding in pain and inflammation, rheumatoid arthritis, osteoarthritis or ankylosing spondylitis and acetylsalicylic acid (Aspirin®), diclofenac or indomethacin, Parkinson's disease and levodopa, malaria and hydroxychloroquine sulfate, high blood pressure and atenolol, diabetes and metformin hydrochloride, edema or chronic renal failure and benzoic acid sulfonamide furan, mild to severe heart failure, left ventricular dysfunction after myocardial infarction, high blood pressure with ventricular ejection fraction ≦40% and furosemide, systemic fungal infection and ketoconazole, hyperlipoproteinemia or hypertriglyceridemia and fenofibrate, heart failure and aldosterone, cancer and doxorubicin, prophylaxis of high blood pressure, angina or cluster headache and verapamil, and atrial fibrillation and sotalol.

[0027] Preferably, the disease may be atrial fibrillation and the biologically active ingredient involved in the treatment or prevention is sotalol.

[0028] Further biologically active ingredients according to the present application may be products of biotechnological or microbiological origin and may be selected, for example, from enzymes, hormones, liquid or solid natural extracts, oligonucleotides, DNA, RNA, mRNA, siRNA, Protacs (targeted proteolytic chimeras), peptide hormones, therapeutic bacteria, prebiotics, probiotics, peptides, proteins, urological drugs, omega-3-fatty acids, anthocyanidins, for example from bilberries, blueberries or blackcurrants as antioxidants, vitamins and vaccines.

[0029] Intermediate Coating Layer The intermediate coating layer (ICL) is on or above the inner core and comprises an alkaline agent. The intermediate coating layer may comprise 5-75% by weight, preferably 10-50% by weight, of an alkaline agent. The intermediate layer may comprise 25-95% by weight, preferably 90-50% by weight, of further pharma- ceutically or nutritionally acceptable excipients, such as polymeric binders, such as neutral water-soluble celluloses, such as hydroxypropylmethylcellulose (HPMC) or hydroxypropylcellulose (HPC) or polyvinylpyrrolidone (PVP), or plasticizers or anti-blocking agents or combinations thereof. The polymeric binders may be neutral or anionic (meth)acrylate copolymers, the latter optionally being partially or fully neutralized. Preferably, the intermediate layer is on the core without any other coating layer in between. The intermediate coating layer may be present in an amount of 5-100% by weight, preferably 7.5-50% by weight, calculated relative to the weight of the core.

[0030] Alkaline agent The alkaline agent may be an alkali metal salt or an alkaline earth metal salt. The alkaline agent may be selected from, for example, calcium oxide, calcium carbonate, magnesium carbonate, magnesium oxide, sodium carbonate, sodium bicarbonate and sodium hydroxide, or any mixture thereof. A preferred alkaline agent is magnesium oxide or magnesium carbonate. The relationship of the alkaline agent in the intermediate coating layer (ICL) to the enteric polymer in the enteric coating layer (ECL) is given by the formula:

number

[0031] Plasticizer A plasticizer can be defined as a material that, through physical interaction with the polymer, achieves a reduction in the glass transition temperature, depending on the amount added, to promote film formation. Suitable materials usually have a molecular weight of 100 to 20,000 and contain one or more hydrophilic groups in the molecule, such as hydroxy esters or amino groups.

[0032] The intermediate coating layer or the enteric coating layer may comprise a plasticizer which may be selected from the group of alkyl citrates, glycerol esters, alkyl phthalates, alkyl sebacates, sucrose esters, sorbitan esters and polyethylene glycols. The intermediate coating layer may comprise, for example, about 2-50% by weight, preferably 5-25% by weight, of a plasticizer which may be selected from triethyl citrate (TEC), acetyl triethyl citrate (ATEC), diethyl and dibutyl sebacate (DBS), glycerol, propylene glycol, polyethylene glycol 200-12,000 and castor oil. A preferred plasticizer for the intermediate coating layer may be glycerin or triethyl citrate. A preferred plasticizer for the enteric coating layer may be triethyl citrate.

[0033] Enteric Coating Layer The enteric coating layer is on or above an intermediate coating layer comprising an enteric polymer and optionally a pharmaceutically or nutritionally acceptable excipient. The enteric coating layer may comprise 10-100% by weight, preferably 20-80% by weight, of an enteric polymer. The enteric coating layer may comprise 90-0% by weight, preferably 80-20% by weight, of a pharmaceutically or nutritionally acceptable excipient, such as a plasticizer. Preferably, the enteric coating layer is on an intermediate coating layer with no other coating layer in between. The enteric coating layer may be present in an amount of 5-50% by weight, calculated on the weight of the core and the intermediate layer.

[0034] Enteric polymers The enteric polymer in the further coating layer on or above the intermediate coating layer may be selected from anionic (meth)acrylate copolymers, anionic celluloses, anionic polysaccharides and polyvinyl acetate phthalates or any mixtures thereof. The enteric coating layer may be present in an amount of 10-50% by weight, calculated on the weight of the core and intermediate layer.

[0035] Anionic (Meth)Acrylate Copolymer The enteric coating layer may comprise a (meth)acrylate copolymer selected from copolymers comprising polymerized units of methacrylic acid and ethyl acrylate, of methacrylic acid and methyl methacrylate, of ethyl acrylate and methyl methacrylate, or of methacrylic acid, methyl acrylate and methyl methacrylate, mixtures of copolymers comprising polymerized units of methacrylic acid and ethyl acrylate with copolymers comprising polymerized units of methyl methacrylate and ethyl acrylate, and mixtures of copolymers comprising polymerized units of methacrylic acid, methyl acrylate and methyl methacrylate with copolymers having polymerized units of methyl methacrylate and ethyl acrylate, and mixtures of any mixtures thereof.

[0036] The coating layer may comprise a (meth)acrylate copolymer comprising 40-60% by weight of polymerized units of methacrylic acid and 60-40% by weight of ethyl acrylate (type EUDRAGIT® L100-55). A suitable second polymer is EUDRAGIT® L100-55 (Evonik Nutrition&Care GmbH, Darmstadt, Germany), which is a copolymer comprising 50% by weight of polymerized units of methacrylic acid and 50% by weight of ethyl acrylate. EUDRAGIT® L30 D-55 is a 30% by weight aqueous dispersion of EUDRAGIT® L100-55. The glass transition temperature T gm is about 110°C.

[0037] The coating layer may comprise a (meth)acrylate copolymer (a type of EUDRAGIT® FS) containing polymerized units of 5-15% by weight methacrylic acid, 60-70% by weight methyl acrylate, and 20-30% by weight methyl methacrylate. A suitable copolymer is EUDRAGIT® FS, which is a copolymer of 25% by weight methyl methacrylate, 65% by weight methyl acrylate, and 10% by weight methacrylic acid polymerized therein. EUDRAGIT® FS 30 D contains 30% by weight EUDRAGIT® FS. The glass transition temperature T gm is about 45°C.

[0038] The coating layer may comprise a (meth)acrylate copolymer comprising polymerized units of 40-60% by weight of methacrylic acid and 60-40% by weight of methyl methacrylate (a type of EUDRAGIT® L100). EUDRAGIT® L100 is a copolymer of 50% by weight of methyl methacrylate and 50% by weight of methacrylic acid polymerized together. The glass transition temperature T gm is about 150° C. or higher.

[0039] The coating layer may comprise a (meth)acrylate copolymer containing polymerized units of 20-40% by weight of methacrylic acid and 60-80% by weight of methyl methacrylate (a type of EUDRAGIT® S100). EUDRAGIT® S100 is a copolymer of 70% by weight of methyl methacrylate and 30% by weight of methacrylic acid polymerized together. The glass transition temperature T gm is about 160° C. or higher.

[0040] The coating layer may also comprise an anionic (meth)acrylate copolymer in the form of a core-shell polymer from two (meth)acrylate copolymers. The coating layer may comprise a (meth)acrylate copolymer, which is a core-shell polymer comprising 50-90% by weight, preferably 70-80% by weight, of a core comprising 60-80% by weight, preferably 65-75% by weight, of ethyl acrylate and 40-20% by weight, preferably 35-25% by weight, of methyl methacrylate, and 50-10% by weight, preferably 30-20% by weight, of a shell comprising 40-60% by weight, preferably 45-55% by weight, of ethyl acrylate and 60-40% by weight, preferably 55-45% by weight, of methacrylic acid.

[0041] A suitable core-shell polymer is EUDRAGIT® FL 30 D-55 (Evonik Nutrition & Care GmbH, Darmstadt, Germany), which is a commercially available 30% by weight aqueous dispersion of a copolymer from a two-stage emulsion polymerization process having about 75% by weight of the core comprising about 70% by weight of polymerized units of ethyl acrylate and 30% by weight of methyl methacrylate, and about 25% by weight of the shell comprising about 50% by weight of ethyl acrylate and 50% by weight of methacrylic acid. The glass transition temperature T gm is about 8°C.

[0042] Anionic Cellulose The anionic cellulose (chemically modified cellulose) may be selected from carboxymethylethylcellulose and its salts, cellulose acetate phthalate, cellulose acetate succinate, cellulose acetate trimellitate, hydroxypropylmethylcellulose phthalate and hydroxypropylmethylcellulose acetate succinate or any mixture thereof.

[0043] Anionic Polysaccharides Anionic polysaccharides (not based on cellulose) having enteric properties may be selected from polymers such as shellac, chitosan, alginic acid and salts of alginic acid, such as sodium alginate, potassium alginate or ammonium alginate.

[0044] Pharmaceutically or dietary acceptable excipients The core in the intermediate layer or the enteric coating layer may optionally contain pharma- ceutically or nutraceutical acceptable excipients, which may be selected from antioxidants, glazing agents, binders such as lactose, polyvinylpyrrolidone or neutral cellulose, flavoring agents, flow aids, glidants, permeation enhancers, pigments, plasticizers, additional polymers, pore-forming agents and stabilizers, or any combination thereof.

[0045] item The present invention may be characterized by the following items.

[0046] 1. A dosage form comprising a biologically active ingredient for use in the treatment or prevention of a disease in the animal or human body, the treatment or prevention requiring a release of 50% or more of the biologically active ingredient in the small intestine within a pH range of 3 to 5.5, the dosage form comprising: a) a core comprising a biologically active ingredient; b) an intermediate coating layer (ICL) on or over the core, the intermediate coating layer comprising an alkaline agent; and c) an enteric coating layer (ECL) on or over the intermediate coating layer, which comprises an enteric polymer; wherein the relationship between the alkaline agent and the enteric polymer is as follows:

number

[0047] 2. The dosage form according to item 1, wherein the release of the biologically active ingredient is 10% or less at pH 1.2 for 120 minutes and 50% or more at pH 3 to 5.5 for 45 minutes.

[0048] 3. The disease and biologically active category for the treatment or prevention of the disease is: gastrointestinal cleansing and laxative, inflammatory bowel disease and corticosteroids, hypercholesterolemia or hypertriglyceridemia and statins, CHF and glycosides, cardiac arrhythmia and stereoisomers of quinidine, cancer and plant alkaloids, bacterial infections and antibiotics, HIV and nucleosides, pancreatic insufficiency and lipase, major depressive disorder (MDD) or seasonal affective disorder (SAD) or smoking cessation and norepinephrine / dopamine reuptake inhibitor (NDRI) support, pain or inflammation and NSAIDs, rheumatoid arthritis, osteoarthritis or ankylosing spondylitis and NSAIDs, Parkinson's disease and 3. The dosage form according to item 1 or 2, selected from dopamine precursors, malaria and antimalarials, hypertension and beta-blockers, diabetes and biguanides, edema or chronic renal failure, and benzoic acid sulfonamide furans, mild to severe heart failure, left ventricular dysfunction after myocardial infarction, hypertension with ventricular ejection fraction ≦40%, beta-adrenergic receptor blockers, systemic fungal infections and antifungals, hyperlipoproteinemia or hypertriglyceridemia and fibrate antilipidemia, heart failure and mineralocorticoid hormones, cancer and anthracycline antibiotics, prophylaxis of hypertension, angina pectoris or cluster headache and calcium channel blockers, atrial fibrillation and beta-blockers.

[0049] 4. The biologically active ingredient related to the treatment or prevention of a disease or condition is gastrointestinal cleansing and bisacodyl, inflammatory bowel disease and budesonide, hypercholesterolemia or hypertriglyceridemia and fluvastatin, CHF and digoxin, cardiac arrhythmia and quinidine, cancer and etoposide, bacterial infection and erythromycin, penicillin G, ampicillin, streptomycin, clarithromycin or azithromycin, HIV and dideoxyinosine (ddI or didanosine), dideoxyadenosine (ddA) or dideoxycytosine (ddC), pancreatic insufficiency and lipase, major depressive disorder (MDD) or seasonal affective disorder (SAD), or smoking cessation and bupropion, aiding in pain and inflammation, rheumatoid arthritis, osteoarthritis or ankylosing spine 4. The dosage form according to any one of items 1 to 3, wherein the therapeutic agent is selected from the group consisting of inflammation and acetylsalicylic acid (Aspirin®), diclofenac or indomethacin, Parkinson's disease and levodopa, malaria and hydroxychloroquine sulfate, hypertension and atenolol, diabetes mellitus and metformin hydrochloride, edema or chronic renal failure and benzoic acid sulfonamide furan, mild to severe heart failure, left ventricular dysfunction after myocardial infarction, hypertension with a ventricular ejection fraction ≦40% and furosemide, systemic fungal infection and ketoconazole, hyperlipoproteinemia or hypertriglyceridemia and fenofibrate, heart failure and aldosterone, cancer and doxorubicin, prophylaxis of hypertension, angina pectoris or cluster headache and verapamil, and atrial fibrillation and sotalol.

[0050] 5. The dosage form according to any one of items 1 to 4, wherein the disease is atrial fibrillation and the biologically active ingredient for treating or preventing the disease is sotalol.

[0051] 6. The dosage form according to any one of items 1 to 5, wherein the core comprises a biologically active ingredient, which is distributed in a matrix structure or bound to a binder in a coating on the inner core.

[0052] 7. The dosage form according to any one of items 1 to 6, wherein the alkaline agent is an alkali metal salt or an alkaline earth metal salt.

[0053] 8. The dosage form according to any one of items 1 to 7, wherein the alkaline agent is selected from calcium oxide, calcium carbonate, magnesium carbonate, magnesium oxide, sodium carbonate, sodium bicarbonate and sodium hydroxide, or any combination thereof.

[0054] 9. The dosage form according to any one of items 1 to 8, wherein the alkaline agent is magnesium carbonate or magnesium oxide.

[0055] 10. The dosage form according to any one of the preceding claims, wherein the intermediate coating layer further comprises a plasticizer and / or a polymeric binder.

[0056] 11. The dosage form according to any one of items 1 to 10, wherein the enteric polymer in the enteric coating layer is selected from anionic (meth)acrylate copolymers, anionic polysaccharides and polyvinyl acetate phthalates or any mixture thereof.

[0057] 12. The dosage form according to any one of items 1 to 11, wherein the anionic (meth)acrylate copolymer is selected from copolymers comprising polymerized units of methacrylic acid and ethyl acrylate, of methacrylic acid and methyl acrylate, and of methacrylic acid, methyl acrylate and methyl methacrylate, or any mixture thereof.

[0058] 13. The dosage form according to any one of items 1 to 12, wherein the anionic cellulose is selected from carboxymethylethylcellulose and its salts, cellulose acetate phthalate, cellulose acetate succinate, cellulose acetate trimellitate, hydroxypropylmethylcellulose phthalate and hydroxypropylmethylcellulose acetate succinate or any mixture thereof.

[0059] 14. The dosage form according to any one of items 1 to 13, wherein the relationship of the alkaline agent to the enteric polymer is 7 to 80%.

[0060] 15. The dosage form according to any one of items 1 to 14, wherein the release of the biologically active ingredient is less than 10% at pH 1.2 in 120 minutes and 60-100% in the range of pH 3.2-5.0 in 45 minutes.

[0061] 16. The dosage form according to any one of items 1 to 15, wherein the core comprises 0.1 to 100% by weight, 1 to 100% by weight, 2 to 90% by weight, 5 to 85% by weight, 10 to 70% by weight or 15 to 50% by weight of the biologically active ingredient.

[0062] 17. The dosage form according to any one of items 1 to 16, wherein the core comprises 0-99.9%, 0-99%, 10-98%, 15-95%, 30-90% or 50-85% by weight of pharma- ceutically or nutraceutical acceptable excipients.

[0063] 18. The dosage form according to any one of items 1 to 17, wherein the biologically active ingredient is selected from acetylsalicylic acid, benazepril, bisascodyl, budesonide, carvedilol, etopside, quinidine, ketoconazole or sotalol, enzymes, hormones, liquid or solid natural extracts, oligonucleotides, DNA, RNA, mRNA, siRNA, Protac (targeted proteolytic chimeras), peptide hormones, therapeutic bacteria, prebiotics, probiotics, peptides, proteins, urological drugs, omega-3-fatty acids, anthocyanidins, e.g. bilberry, blueberry or blackcurrant, vitamins and vaccines.

[0064] 19. The dosage form according to any one of items 1 to 18, wherein the intermediate coating layer (ICL) is present in an amount of 5 to 100% by weight, calculated on the weight of the core.

[0065] 20. The dosage form according to any one of items 1 to 19, wherein the intermediate coating layer (ICL) is present in an amount of 7.5 to 50% by weight, calculated on the weight of the core.

[0066] 21. The dosage form according to any one of items 1 to 20, wherein the intermediate coating layer (ICL) comprises 5 to 75% by weight of an alkaline agent.

[0067] 22. The dosage form according to any one of items 1 to 21, wherein the intermediate coating layer (ICL) comprises 10 to 50% by weight of an alkaline agent.

[0068] 23. The dosage form according to any one of items 1 to 22, wherein the enteric coating layer (ECL) is present in an amount of 10 to 50% by weight, calculated on the weight of the core and intermediate layer.

[0069] 24. The dosage form according to any one of items 1 to 23, wherein the enteric coating layer (ECL) comprises 10 to 100% by weight of an enteric polymer.

[0070] 25. The dosage form according to any one of items 1 to 24, wherein the enteric coating layer (ECL) comprises 20 to 80% by weight of an enteric polymer.

[0071] 26. The dosage form of any one of items 1 to 25, wherein the enteric polymer comprises a (meth)acrylate copolymer comprising polymerized units of 40 to 60% by weight of methacrylic acid and 60 to 40% by weight of ethyl acrylate.

[0072] Working Example: A. Preparation of the core: 1. Benazepril (Core) Tablets: 1.1 Composition of Benazepril tablets: [Table 1]

[0073] 1.2 Method for Benazepril Tablets: I. Weigh out all ingredients specified in the recipe. II. Benazepril hydrochloride and lactose monohydrate were mixed uniformly and sieved through a #40 mesh. III. Microcrystalline Cellulose PH101 and half the amount of HPMC 6cps, were sieved through #40 mesh and added to Step II. IV. The powder blend of step III was added to the rapid mixer granulator and mixed on low speed for 5 minutes. V. In a separate beaker, the remaining half amount of HPMC 6 cps was slowly added in purified water under continuous stirring to obtain a clear solution. VI. The binder solution of step V was then used to granulate the dry blend of step IV. VII. After granulation, sieve the wet material through a 10# (2.0 mm) sieve. VIII. The granules were dried in a tray dryer at 50° C. until the LOD was less than 5% (w / w). IX. The dried granules were passed through a 30# (595 μm) sieve. X. All extra-granular materials were accurately weighed. XI. MCC PH 102, croscarmellose sodium and Aerosil 200 were mixed in a polybag and sieved through #40 mesh. XII. Benazepril granules from Step IX and the sieved material from Step XI were mixed in a double cone blender at 15 RPM for 15 minutes. XIII. Sieved Magnesium stearate (60#) was added to step XII to lubricate the blend in a double cone blender at 15 RPM for 3 minutes. XIV. The lubricated blend was used for tablet compression. [Table 2]

[0074] 2. Sotalol (Core) Tablets: 2.1 Composition of Sotalol tablets: [Table 3]

[0075] 2.2 Method for Sotalol tablets: I. Weigh out all ingredients specified in the recipe. II. Sotalol hydrochloride, microcrystalline cellulose and Ac-Di-Sol® were mixed uniformly and sieved through a #30 mesh. III. The powder blend of Step II was added to the rapid mixer granulator and mixed on low speed for 3 minutes. IV. In a separate beaker, HPMC 3 cps was slowly added in purified water under continuous stirring to obtain a clear solution. V. The solution of step IV was then used to granulate the dry blend of step III. VI. The granules were dried in a tray dryer at 60° C. for 2 hours and passed through a 30# sieve and further dried at 60° C. for 4 hours until the LOD was less than 5% (w / w). VII. The dried granules were passed through a 30# (595 μm) sieve. VIII. All extra-granular materials were accurately weighed. IX. Microcrystalline Cellulose PH101, Ac-Di-Sol® and Aerosil 200 were mixed in a polybag and sieved through a #30 mesh. X. The sotalol granules from Step VII and the sieved material from Step IX were mixed in a double cone blender at 15 RPM for 15 minutes. XI. Magnesium stearate (passed through 60#) was added to the Step X blend and lubricated in a double cone blender at 15 RPM for 5 minutes. XII. The lubricated blend was used for tablet compression. [Table 4]

[0076] B. Coating: 1. Coating composition for the present experiments: [Table 5]

[0077] 2. Coating method for the present experiment: 2.1 Intermediate Coating: 2.1.1 Intermediate coatings for experiments I1 and I3: I. All ingredients were weighed out in the amounts required. II. HPMC [3 cps] was dissolved in water containing glycerin using an overhead stirrer until a clear solution was obtained. III. Magnesium oxide was slowly added to the above solution with stirring and the resulting suspension was allowed to mix for 30 minutes. IV. The suspension was passed through a 100# sieve and used for intermediate coating.

[0078] 2.1.2 Intermediate coating for experiment I2: I. All ingredients were weighed out in the amounts required. II. HPMC [3 cps] was dissolved in water containing glycerin using an overhead stirrer until a clear solution was obtained. III. Magnesium carbonate was slowly added to the above solution with stirring and the resulting suspension was allowed to mix for 30 minutes. IV. The suspension was passed through a 40# sieve and used for intermediate coating. [Table 6]

[0079] 2.2 Enteric Coating: 2.2.1 Enteric Coatings for Experiments I1-I3: I. All ingredients were weighed out in the amounts required. II. The TEC and talc were homogenized in water for 15 minutes and then slowly added to the EUDRAGIT® L30 D-55 dispersion with stirring, and the resulting suspension was mixed for 30 minutes using an overhead stirrer. III. The suspension was passed through a 40# sieve and used for seal coating. [Table 7]

[0080] C. Analysis of Enteric Coated Pellets / Tablets: Analysis method 1. Benazepril tablets A) Dissolution conditions 1) Solubility parameters Apparatus: USP Type II Dissolution media: Acidic stage media for 2 hours, followed by buffer stage media (1 hour) Volume of medium: 750mL for acidic stage, 1000mL for buffer stage Speed:50rpm Temperature: 37℃±0.5℃ Amount withdrawn: 10ml.

[0081] 2) Dissolution medium I. Acidic stage medium - 0.1NHCl; Buffer stage medium - pH 5.5 buffer II. Acidic stage medium - 0.1NHCl; Buffer stage medium - pH 4.5 buffer III. Acidic stage medium - 0.1NHCl; buffer stage medium - pH 3.0 buffer.

[0082] 3) Composition of the dissolution medium 1) Buffer pH5.5- Approximately 1 g of potassium dihydrogen phosphate, 2 g of dipotassium hydrogen phosphate, and 8.5 g of sodium chloride were accurately weighed and transferred to a 1 litre beaker. To this was added 500 mL of water to dissolve the salts and the volume was made up to 1000 mL with water. The pH was adjusted to 5.5 (±0.05) using orthophosphoric acid. 2) Buffer pH4.5- Approximately 1 g of potassium dihydrogen phosphate, 2 g of dipotassium hydrogen phosphate, and 8.5 g of sodium chloride were accurately weighed and transferred to a 1 litre beaker. To this was added 500 mL of water to dissolve the salts and the volume was made up to 1000 mL with water. The pH was adjusted to 4.5 (±0.05) using orthophosphoric acid. 3) Buffer pH3.0- Approximately 1 g of potassium dihydrogen phosphate, 2 g of dipotassium hydrogen phosphate, and 8.5 g of sodium chloride were accurately weighed and transferred to a 1 litre beaker. To this was added 500 mL of water to dissolve the salts and the volume was made up to 1000 mL with water. The pH was adjusted to 3.0 (±0.05) using orthophosphoric acid.

[0083] 4) Dissolution procedure: Acid stage: Benazepril hydrochloride tablets were transferred into different dissolution jars and dissolution test was carried out according to the given parameters in the above method (acid stage).After 2 hours, 10 mL aliquot was taken and analyzed as sample solution of acid stage. Buffer stage: The tablets after the acid stage were transferred to the buffer stage medium. The dissolution test was continued according to the parameters given in the method (buffer stage). The aliquots at each interval were filtered through a 0.45 μm nylon membrane syringe filter, the first few mL of the filtrate were discarded and analyzed as the buffer stage sample solution.

[0084] B) Chromatographic conditions Column: Agilent Zorbax Eclipse XDB C18 column, 150 x 4.6 mm, 5 μm or equivalent Mobile phase: Buffer: MeOH (36:64) Wavelength: 240nm Column temperature: 25℃ Injection volume: 20 μL Flow rate: 1mL / min Preparation of buffer for mobile phase: An accurately weighed amount of 2.25 g of tetrabutylammonium bromide was transferred to 500 mL of water and dissolved. 0.55 mL of glacial acetic acid was added to it and made up to 1000 mL with water. The buffer was filtered through a 0.45 μm nylon membrane filter.

[0085] 2. Sotalol tablets: A) Dissolution conditions 1) Solubility parameters Apparatus: USP Type II Dissolution media: Acidic stage media for 2 hours, followed by buffer stage media (1 hour) Volume of medium: 750mL for acidic stage, 1000mL for buffer stage Speed:50rpm Temperature: 37℃±0.5℃ Amount withdrawn: 10ml.

[0086] 2) Dissolution medium IV. Acidic stage medium - 0.1NHCl; Buffer stage medium - pH 5.5 buffer V. Acidic stage medium - 0.1NHCl; Buffer stage medium - pH 4.5 buffer VI. Acidic stage medium - 0.1NHCl; buffer stage medium - pH 3.0 buffer.

[0087] 3) Composition of the dissolution medium 1) Buffer pH5.5- Approximately 1 g of potassium dihydrogen phosphate, 2 g of dipotassium hydrogen phosphate, and 8.5 g of sodium chloride were accurately weighed and transferred to a 1 litre beaker. To this was added 500 mL of water to dissolve the salts and the volume was made up to 1000 mL with water. The pH was adjusted to 5.5 (±0.05) using orthophosphoric acid. 2) Buffer pH4.5- Approximately 1 g of potassium dihydrogen phosphate, 2 g of dipotassium hydrogen phosphate, and 8.5 g of sodium chloride were accurately weighed and transferred to a 1 litre beaker. To this was added 500 mL of water to dissolve the salts and the volume was made up to 1000 mL with water. The pH was adjusted to 4.5 (±0.05) using orthophosphoric acid. 3) Buffer pH3.0- Approximately 1 g of potassium dihydrogen phosphate, 2 g of dipotassium hydrogen phosphate, and 8.5 g of sodium chloride were accurately weighed and transferred to a 1 litre beaker. To this was added 500 mL of water to dissolve the salts and the volume was made up to 1000 mL with water. The pH was adjusted to 3.0 (±0.05) using orthophosphoric acid.

[0088] 4) Dissolution procedure: Acid stage: Sotalol tablets were transferred into different dissolution jars and dissolution test was carried out as per the given parameters in the above method (acid stage).After 2 hours, 10 mL aliquot was taken and analyzed as sample solution for acid stage. Buffer stage: The tablets after the acid stage were transferred to the buffer stage medium. The dissolution test was continued according to the parameters given in the method (buffer stage). The aliquots at each interval were filtered through a 0.45 μm nylon membrane syringe filter, the first few mL of the filtrate were discarded and analyzed as the buffer stage sample solution. B) Chromatographic conditions Column: Agilent Zorbax Eclipse XDB C18 column, 150 x 4.6 mm, 5 μm or equivalent Mobile phase: Buffer:ACN (90:10) Wavelength: 238nm Column temperature: 25℃ Injection volume: 20 μL Flow rate: 1.5mL / min Preparation of buffer for mobile phase: An accurately weighed amount of 6.8 g of potassium dihydrogen orthophosphate was dissolved in 1000 mL of water. The buffer was filtered through a 0.45 μm nylon membrane filter.

[0089] D. Summary: [Table 8]

[0090] E. Preparation of Cores: 1. Sotalol tablets: Composition and Methods of Sotalol Tablets for Experiments C1 and C2: See Core Preparation for Experiment I3.

[0091] 2. Pantoprazole pellets: 2.1 Composition of Pantoprazole Pellets (Drug Layering Method): [Table 9]

[0092] 2.2 Method for Pantoprazole Pellets: I. All ingredients were weighed out in the amounts required. II. HPMC [6 cps] was dissolved in water using an overhead stirrer until a clear solution was obtained. III. Pantoprazole sodium sesquihydrate was sieved through a 40# (400 μm) sieve and added to the solution of step II under continuous stirring. Stirring was continued until a clear solution was obtained. IV. The drug solution of step III was sieved through a 40# sieve and used for drug layering on NPS 20 / 25#. [Table 10]

[0093] 3. Benazepril pellets: 3.1 Composition of Benazepril (core) pellets: [Table 11]

[0094] 3.2 Process of preparation of Benazepril pellets for experiments C4 and C5: I. All ingredients were accurately weighed. II. Benazepril hydrochloride and lactose monohydrate were dissolved in sufficient amount of purified water under continuous stringing. III. In a beaker, 3 cps of HPMC was dissolved in purified water under stirring. IV. Aerosil® 200 was homogenized in purified water for 15 minutes. V. The solution from step II was added to step III under stirring. VI. The dispersion of step IV was then added to step V under stirring. VII. The suspension of step VI was then filtered through #60 mesh and used for drug layering with NPS. [Table 12]

[0095] F. Coating: 1. Coating composition of seal coating, intermediate coating and enteric coating for comparative experiments: [Table 13]

[0096] 2. Seal Coating, Intermediate Coating and Enteric Coating Methods: 2.1 Seal Coating: 2.1.1 Seal coating process for experiment C3: I. All ingredients were weighed out in the amounts required. II. HPMC [6 cps] was dissolved in water using an overhead stirrer until a clear solution was obtained. III. The talc was slowly added to the solution from step II with stirring and the resulting suspension was allowed to mix for 30 minutes. IV. The suspension was passed through a 40# sieve and used for seal coating. [Table 14]

[0097] 2.2 Intermediate Coating: 2.2.1 Process of intermediate coating in experiment C2: I. All ingredients were accurately weighed. II. A weighed amount of talc was dispersed in purified water under homogenizer for 30 minutes. III. A separately prepared citric acid solution was added in step II. IV. A 1N NaOH solution was prepared as required for neutralization of EUDRAGIT® L30D-55. V. In a separate glass beaker, TEC and Tween 80 were added to the warm purified water to form a clear solution. VI. Then the solution of step V was added to the dispersion of step II under overhead stirring for 10-15 minutes. VII. The required amount of EUDRAGIT® L30D-55 was added to the dispersion from Step II and mixed. VIII. The dispersion of Step VII was neutralized with the solution of Step IV under continuous stirring to form a clear dispersion having the required pH. IX. The suspension was passed through a 40# sieve and used for intermediate coating. [Table 15]

[0098] 2.2.2 Process of intermediate coating in experiment C3: I. All ingredients were weighed out in the amounts required. II. Pharmacoat 606 was dissolved in purified water using an overhead stirrer. III. Magnesium carbonate was slowly added to the above solution with stirring and the resulting suspension was allowed to mix for 30 minutes. IV. The suspension was passed through a 40# sieve and used for intermediate coating. [Table 16]

[0099] 2.2.3 Process for intermediate coating of experiment C5: I. All ingredients were weighed out in the amounts required. II. Glycerin was dissolved in purified water. III. HPMC (3 cps) was dissolved in step II using an overhead stirrer until a clear solution was obtained. IV. Magnesium oxide was slowly added to the above solution with stirring and the resulting suspension was allowed to mix for 30 minutes. V. The suspension was passed through a 40# sieve and used for intermediate coating of drug layered pellets.

[0100] 2.3 Enteric Coating: 2.3.1 Enteric coating process for experiments C1 and C2: I. Weigh out all ingredients specified in the recipe. II. A weighed amount of talc was dispersed in purified water under homogenizer for 30 minutes. III. In a separate glass beaker, TEC was added to warm purified water to form a clear solution. IV. The solution from Step III was added to the dispersion from Step II under an overhead stirrer for 15 minutes. V. A weighed amount of EUDRAGIT® L30D-55 dispersion was added to the dispersion from Step IV and mixed. V. The prepared dispersion was passed through a 40# sieve and used for seal coating.

[0101] 2.3.2 Enteric coating process of experiment C3: I. All ingredients were weighed out in the amounts required. II. The TEC and talc were homogenized in water for 15 minutes and then slowly added to the EUDRAGIT® L30 D-55 dispersion with stirring, and the resulting suspension was mixed for 30 minutes using an overhead stirrer. III. The suspension was passed through a 40# sieve and used for seal coating.

[0102] 2.3.3 Enteric coating process of experiment C4: I. All ingredients were weighed out in the amounts required. II. Add EUDRAGIT L30D-55 to 60% of the water under stirring. III. Use some of the remaining water to prepare a 1N sodium hydroxide solution. IV. Slowly add Step III to Step II under stirring. V. Add the TEC and talc to the remaining water and homogenize it for 30 minutes. VI. Add Step V to Step IV under stirring and continue stirring for 20 minutes. VII. The suspension was passed through a 40# sieve and used for intermediate coated enteric coating.

[0103] 2.3.4 Enteric coating process of experiment C5: I. All ingredients were weighed out in the amounts required. II. The TEC and talc were homogenized in water for 15 minutes and then slowly added to the EUDRAGIT® L30 D-55 dispersion with stirring, and the resulting suspension was mixed for 30 minutes using an overhead stirrer. III. The suspension was passed through a 40# sieve and used for mid-coated enteric coating. [Table 17] [Table 18]

[0104] G. Analysis of Enteric Coated Tablets / Pellets: Analysis method 1. Sotalol Tablets: See analytical method in Step D(2).

[0105] 2. Pantoprazole pellets: A) Dissolution conditions 1) Solubility parameters Apparatus: USP Type II Dissolution media: Acidic stage media for 2 hours, followed by buffer stage media (1 hour) Volume of medium: 1000mL for acidic stage, 1000mL for buffer stage Speed: 50rpm Temperature: 37℃±0.5℃ Amount taken: 10ml Sample dilution: Immediately dilute a 10 mL aliquot with 2 mL of 0.5 N sodium hydroxide solution.

[0106] 2) Dissolution medium I. Acidic stage medium - 0.1NHCl; Buffer stage medium - pH 5.5 buffer II. Acidic stage medium - 0.1NHCl; buffer stage medium - pH 4.5 buffer.

[0107] 3) Composition of the dissolution medium 1) Buffer pH5.5- Approximately 1 g of potassium dihydrogen phosphate, 2 g of dipotassium hydrogen phosphate, and 8.5 g of sodium chloride were accurately weighed and transferred to a 1 litre beaker. To this was added 500 mL of water to dissolve the salts and the volume was made up to 1000 mL with water. The pH was adjusted to 5.5 (±0.05) using orthophosphoric acid. 2) Buffer pH4.5- Accurately weigh out approximately 2.99 g of sodium acetate trihydrate and transfer it to a 1 liter beaker. Add water to dissolve and make up to 1000 mL. Adjust the pH to 4.5 (±0.05) using glacial acetic acid. 3) Buffer pH3.0- Accurately weigh approximately 8.98 grams of anhydrous citric acid and 2.13 grams of trisodium citrate dihydrate into 1000 ml of water. Sonicate to dissolve. Adjust pH to 3.5 (±0.05) using dilute NaOH.

[0108] 4) Dissolution procedure: Acid stage: Accurately weighed pantoprazole pellets were transferred into different dissolution jars and dissolution test was carried out according to the given parameters in the method (acid stage). After 2 hours, 10 mL aliquots were taken and filtered through 0.45 μm PVDF membrane syringe filter. 1 mL was immediately diluted with 1 mL of 0.5 N sodium hydroxide solution and analyzed as the sample solution of acid stage. Buffer stage: The pellet after the acid stage was transferred to the buffer stage medium. The dissolution test was continued according to the parameters given in the method (buffer stage). An aliquot at each interval was filtered through a 0.45 μm PVDF membrane syringe filter and the first few mL of the filtrate was discarded. 1 mL was immediately diluted with 1 mL of 0.5 N sodium hydroxide solution and analyzed as the sample solution of the buffer stage.

[0109] B) Chromatographic conditions Chromatography conditions Column: Agilent Zorbax XDB Eclipse C8 column, 150 x 4.6 mm, 5 μm Mobile phase: Water: acetonitrile: triethylamine (60:40:1), pH adjusted to 7.0 (+0.05) with orthophosphoric acid Wavelength: 290nm Column temperature: 30℃ Injection volume: 10μL Flow rate: 1.0mL / min.

[0110] 3. Benazepril pellets: A) Dissolution conditions 1) Solubility parameters Apparatus: USP Type II Dissolution media: Acidic stage media for 2 hours, followed by buffer stage media (1 hour) Volume of medium: 750 mL for acidic stage, 1000 mL for buffer stage Speed: 50rpm Temperature: 37℃±0.5℃ Amount withdrawn: 10ml.

[0111] 2) Dissolution medium I. Acidic stage medium 0.1NHCl; Buffer stage medium - pH 5.5 buffer II. Acidic stage medium 0.1NHCl; Buffer stage medium - pH 4.5 buffer III. Acidic stage medium 0.1NHCl; Buffer stage medium - pH 3.0 buffer.

[0112] 3) Composition of the dissolution medium 1) Buffer pH5.5- Approximately 1 g of potassium dihydrogen phosphate, 2 g of dipotassium hydrogen phosphate, and 8.5 g of sodium chloride were accurately weighed and transferred to a 1 litre beaker. To this was added 500 mL of water to dissolve the salts and the volume was made up to 1000 mL with water. The pH was adjusted to 5.5 (±0.05) using orthophosphoric acid. 2) Buffer pH4.5- Approximately 1 g of potassium dihydrogen phosphate, 2 g of dipotassium hydrogen phosphate, and 8.5 g of sodium chloride were accurately weighed and transferred to a 1 litre beaker. To this was added 500 mL of water to dissolve the salts and the volume was made up to 1000 mL with water. The pH was adjusted to 4.5 (±0.05) using orthophosphoric acid. 3) Buffer pH3.0- Approximately 1 g of potassium dihydrogen phosphate, 2 g of dipotassium hydrogen phosphate, and 8.5 g of sodium chloride were accurately weighed and transferred to a 1 litre beaker. To this was added 500 mL of water to dissolve the salts and the volume was made up to 1000 mL with water. The pH was adjusted to 3.0 (±0.05) using orthophosphoric acid.

[0113] 4) Dissolution procedure: Acid stage: Accurately weighed pellets of Benazepril HCl were transferred into different dissolution jars and dissolution test was carried out according to the given parameters in the above method (acid stage). After 2 hours, 10 mL aliquot was taken and analyzed as sample solution of acid stage. Buffer stage: The pellet after the acid stage was transferred to the buffer stage medium. The dissolution test was continued according to the parameters given in the method (buffer stage). Aliquots at each interval were filtered through a 0.45 μm nylon membrane syringe filter, the first few mL of the filtrate were discarded, and analyzed as the buffer stage sample solution.

[0114] B) Chromatographic conditions Column: Agilent Zorbax Eclipse XDB C18 column, 150 x 4.6 mm, 5 μm or equivalent Mobile phase: Buffer: MeOH (36:64) Wavelength: 240nm Column temperature: 25℃ Injection volume: 20 μL Flow rate: 1mL / min Preparation of buffer for mobile phase: An accurately weighed amount of 2.25 g of tetrabutylammonium bromide was transferred to 500 mL of water and dissolved. 0.55 mL of glacial acetic acid was added to it and made up to 1000 mL with water. The buffer was filtered through a 0.45 μm nylon membrane filter.

[0115] H. Summary: [Table 19] [Table 20]

Claims

1. 1. A pharmaceutical formulation comprising a biologically active ingredient for use in the treatment or prevention of a disease in the animal or human body, the treatment or prevention requiring a release of 50% or more of the biologically active ingredient in the small intestine within a pH range of 3 to 5.5, the pharmaceutical formulation comprising: a) a core comprising a biologically active ingredient; b) an intermediate coating layer (ICL) on or over the core, comprising an alkaline agent; and c) an enteric coating layer (ECL) on or over the intermediate coating layer, comprising an enteric polymer; wherein the relationship between the alkaline agent and the enteric polymer is as follows: [0010] This is calculated to be 5 to 95%. The release of the biologically active ingredient is less than 10% at pH 1.2 for 120 minutes and more than 50% at pH 3-5.5 for 45 minutes; and The pharmaceutical formulations described above, wherein the biologically active ingredient is a proton pump inhibitor belonging to the class of substituted benzimidazole compounds.

2. The categories of diseases and biologically active ingredients for the treatment or prevention of diseases include gastrointestinal cleansing and laxatives, inflammatory bowel disease and corticosteroids, hypercholesterolemia or hypertriglyceridemia and statins, CHF and glycosides, arrhythmia and stereoisomers of quinidine, cancer and plant alkaloids, bacterial infections and antibiotics, HIV and nucleosides, pancreatic insufficiency and lipase, major depressive disorder (MDD) or seasonal affective disorder (SAD) or smoking cessation and norepinephrine / dopamine reuptake inhibitor (NDRI) support, pain or inflammation and NSAIDs, rheumatoid arthritis, osteoarthritis or ankylosing spondylitis and NSAIDs, Parkinson's disease and dopamine reuptake inhibitors (NDRIs), and the like.

2. The pharmaceutical formulation according to claim 1, wherein the therapeutic agent is selected from the group consisting of: vasopressin precursors, malaria and antimalarials, hypertension and beta-blockers, diabetes and biguanides, edema or chronic renal failure and benzoic acid sulfonamide furans, mild to severe heart failure, left ventricular dysfunction after myocardial infarction with hypertension with ventricular ejection fraction ≦40% and beta-adrenergic receptor blockers, systemic fungal infections and antifungals, hyperlipoproteinemia or hypertriglyceridemia and fibrate antilipidemia, heart failure and mineralocorticoid hormones, cancer and anthracycline antibiotics, prophylaxis of hypertension, angina pectoris or cluster headache and calcium channel blockers, atrial fibrillation and beta-blockers.

3. The biologically active ingredient(s) relating to the disease and the treatment or prevention of the disease may be gastrointestinal cleansing and bisacodyl, inflammatory bowel disease and budesonide, hypercholesterolemia or hypertriglyceridemia and fluvastatin, CHF and digoxin, cardiac arrhythmia and quinidine, cancer and etoposide, bacterial infection and erythromycin, penicillin G, ampicillin, streptomycin, clarithromycin or azithromycin, HIV and dideoxyinosine (ddI or didanosine), dideoxyadenosine (ddA) or dideoxycytosine (ddC), pancreatic insufficiency and lipase, major depressive disorder (MDD) or seasonal affective disorder (SAD), or smoking cessation and bupropion, aiding in pain and inflammation, rheumatoid arthritis, osteoarthritis or ankylosis.

3. The pharmaceutical preparation according to claim 1 or 2, which is selected from spondylitis and acetylsalicylic acid (Aspirin®), diclofenac or indomethacin, Parkinson's disease and levodopa, malaria and hydroxychloroquine sulfate, hypertension and atenolol, diabetes mellitus and metformin hydrochloride, edema or chronic renal failure and benzoic acid sulfonamidofuran, mild to severe heart failure, left ventricular dysfunction after myocardial infarction with hypertension with a ventricular ejection fraction ≦40% and furosemide, systemic fungal infection and ketoconazole, hyperlipoproteinemia or hypertriglyceridemia and fenofibrate, heart failure and aldosterone, cancer and doxorubicin, prophylaxis of hypertension, angina pectoris or cluster headache and verapamil, and atrial fibrillation and sotalol.

4. 4. The pharmaceutical formulation according to any one of claims 1 to 3, wherein the disease is atrial fibrillation and the biologically active ingredient for treating or preventing the disease is sotalol.

5. 5. The pharmaceutical formulation of claim 1, wherein the core comprises a biologically active ingredient that is distributed in a matrix structure or bound to a binder in a coating on the inner core.

6. 6. The pharmaceutical formulation according to any one of claims 1 to 5, wherein the alkaline agent is an alkali metal salt or an alkaline earth metal salt.

7. 7. The pharmaceutical formulation of claim 1, wherein the alkaline agent is selected from calcium oxide, calcium carbonate, magnesium carbonate, magnesium oxide, sodium carbonate, sodium bicarbonate and sodium hydroxide, or any combination thereof.

8. 8. The pharmaceutical formulation according to any one of claims 1 to 7, wherein the alkaline agent is magnesium carbonate or magnesium oxide.

9. 9. The pharmaceutical formulation according to any one of claims 1 to 8, wherein the intermediate coating layer further comprises a plasticizer and / or a polymeric binder.

10. 10. The pharmaceutical formulation according to any one of claims 1 to 9, wherein the enteric polymer in the enteric coating layer is selected from anionic (meth)acrylate copolymers, anionic celluloses, anionic polysaccharides and polyvinyl acetate phthalates or any mixture thereof.

11. 11. The pharmaceutical formulation of claim 10, wherein the anionic (meth)acrylate copolymer is selected from copolymers containing polymerized units of methacrylic acid and ethyl acrylate, of methacrylic acid and methyl acrylate, and of methacrylic acid, methyl acrylate and methyl methacrylate, or any mixture thereof.

12. 11. The pharmaceutical formulation of claim 10, wherein the anionic cellulose is selected from carboxymethylethylcellulose and its salts, cellulose acetate phthalate, cellulose acetate succinate, cellulose acetate trimellitate, hydroxypropylmethylcellulose phthalate and hydroxypropylmethylcellulose acetate succinate or any mixture thereof.

13. 13. The pharmaceutical formulation according to any one of claims 1 to 12, wherein the intermediate coating layer is present in an amount of 5 to 100% by weight, preferably 7.5 to 50% by weight, calculated relative to the weight of the core.

14. A pharmaceutical formulation according to any one of claims 1 to 13, wherein the enteric coating layer is present in an amount of 5 to 50% by weight, calculated on the weight of the core and of the intermediate layer.

Images